Therapy of stage IV B anaplastic thyroid carcinoma: Single institution experience

Journal of B.U.ON.

Volumn 14, Issue 1, 2009, Pages 41-44

  Vrbic, Svetislav ^a,b   Pejcic, I ^a,b   Vrbic, M ^a,b   Filipovic, S ^a,b  

^a Clinical Centre Nis   (Serbia)

^b Facutty of Medicine   (Serbia)

Author keywords

Anaplastic thyroid carcinoma; Chemotherapy; Radiotherapy; Response; Survival; Toxicity

Indexed keywords

CISPLATIN; DOXORUBICIN;

ADULT; AGED; ALOPECIA; ANAPLASTIC CARCINOMA; ANEMIA; ARTICLE; BLOOD TOXICITY; BONE MARROW TOXICITY; CANCER RADIOTHERAPY; CARDIOVASCULAR DISEASE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DISTANT METASTASIS; FEMALE; GASTROINTESTINAL TOXICITY; HEART LEFT VENTRICLE EJECTION FRACTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; LEUKOPENIA; MALE; NAUSEA; NEPHROTOXICITY; OVERALL SURVIVAL; PATIENT COMPLIANCE; SIDE EFFECT; SURVIVAL RATE; THROMBOCYTE COUNT; THYROID CARCINOMA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DOXORUBICIN; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; NEOPLASM STAGING; PATIENT COMPLIANCE; RADIOTHERAPY, ADJUVANT; THYROID NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME;

EID: 64249120699     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Guiffrida D, Lavenia G, Aiello RA et al. Anaplastic carcinoma of the thyroid: diagnosis and treatment. Clin Ther 2001; 152: 255-261.
2. Kebebew E, Greenspan FS, Clark OH, Woeber KA, McMillan A. Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer 2005; 103: 1330-1335.
3. Are C, Shaha AR. Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors and treatment approaches. Ann Surg Oncol 2006; 13: 453-464.
4. Cornett WR, Sharma AK, Day TA et al. Anaplastic thyroid carcinoma: an overview. Curr Oncol Rep 2007; 9: 152-158.
5. Ain KB. Anaplastic thyroid carcinoma; a therapeutic challenge. Semin Surg Oncol 1999; 16: 64-69.
6. Santarpia L, El-Naggar AK, Cote GJ, Myers JN, Sherman SI. Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer. J Clin Endocrinol Metabol 2008; 93: 278-284.
7. Kitamura Y, Shimizu K, Tanaka S, Ito K, Emi M. Allelotyping of anaplastic thyroid carcinoma: frequent allelic losses on 1 q, 9p, 11, 17, 19p, and 22q. Genes Chromosomes Cancer 2000; 27: 244-251.
8. Quiros RM, Ding HG, Gattuso P, Prinz RA, Xu X. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations. Cancer 2005; 103: 2261-2268.
9. Akaishi J, Onda M, Okamoto J et al. Down-regulation of an inhibitor of cell growth, transmembrane protein 34 (TMEM34) in anaplastic thyroid cancer. J Cancer Res Clin Oncol 2007; 133: 213-218.
10. Lang BH, Lo CY. Surgical options in undifferentiated thyroid carcinoma. World J Surg 2007; 31: 969-977.
11. Pasieka JL. Anaplastic thyroid cancer. Curr Opin Oncol 2003; 15: 78-83.
12. Ain KB. Anaplastic thyroid carcinoma: behavior, biology and therapeutic approaches. Thyroid 1998; 8: 715-726.
13. Ain KB, Egorin MJ, DeSimone PA. Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group. Thyroid 2000; 10: 587-594.
14. Suzuki S. Differential diagnosis and strategy for the treatment of anaplastic thyroid carcinoma. Nippon Rinsho 2007; 65: 2079-2086.
15. De Crevoisier R, Bauding E, Bachelot A et al. Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy. Int J Radiat Oncol Biol Phys 2004; 60: 1137-1143.
16. Heron DE, Karimpour S, Grigsby PW. Anaplastic thyroid carcinoma: comparison of conventional radiotherapy and hyperfractionation chemoradiotherapy in two groups. Am J Clin Oncol 2002; 25: 442-446.
17. Goutsouliak V, Hay JH. Anaplastic thyroid cancer in British Columbia 1985-1999: a population-based study. Clin Oncol 2005; 17: 75-78.
18. Amodeo C, Caglia P, Gandolfo L, Veroux M, Donati M, Imme A. Undifferentiated carcinoma of the thyroid. Tumori 2003; 89(4 Suppl): 206-206.
19. Carvalho GA, Graf H. Anaplastic thyroid carcinoma. Arq Bras Endocrinol Metabol 2005; 49: 719-724.
20. Guiffrida D, Gharib H. Anaplastic thyroid carcinoma: current diagnosis and treatment. Ann Oncol 2001; 11: 1083-1089.
21. Chang HS, Nam KH, Chung WY, Park CS. Anaplastic thyroid carcinoma: a therapeutic dilemma. Yonsei Med J 2005; 46: 759-764.
22. Haigh PI, Ituarte PH, Wu HS et al. Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival. Cancer 2001; 91: 2335-2342.
23. Busnardo B, Daniele O, Pellizzo MR et al. A multimodality therapeutic approach in anaplastic thyroid carcinoma: study on 39 patients. J Endocrinol Invest 2000; 23: 755-761.
24. Brignadello E, Gallo M, Baldi I et al. Anaplastic thyroid carcinoma: clinical outcome of 30 consecutive patients referred to a single institution in the past 5 years. Eur J Endocrinol 2007; 156: 425-430.
25. Besic N, Auersperg M, Us-Krasovec M, Golouh R, Erković-Grazio S, Vodnik A. Effect of primary treatment on survival in anaplastic thyroid carcinoma. Eur J Surg Oncol 2001; 27: 260-264.
26. McIver B, Hay ID, Guiffrida DF et al. Anaplastic thyroid carcinoma: a 50-year experience at a single institution. Surgery 2001; 130: 1928-1034.
27. Pierie JP, Muzikansky A, Gaz RD, Faquin WC, Ott MJ. The effect of surgery and radiotherapy on outcome of anaplastic thyroid carcinoma. Ann Surg Oncol 2002; 9: 57-64.
28. Wiseman SM, Griffith OL, Deen S et al. Identification of molecular markers altered during transformation of differentiated into anaplastic thyroid carcinoma. Arch Surg 2007; 142: 717-727.
29. Wiswman SM, Masoudi H, Niblock P et al. Anaplastic thyroid carcinoma: expression profile of targets for therapy offers new insights for disease treatment. Ann Surg Oncol 2007; 14: 719-729.
30. Libertini S, Iacuzzo I, Ferraro A et al. Lovastatin enhances the replication of the oncolytic adenovirus dl1520 and its antineoplastic activity against anaplastic thyroid carcinoma cells. Endocrinology 2007; 148: 5186-5194.